Business, energy, technology, markets and global industry news from Business News Today

U.S. Food and Drug Administration

PharmaDeviceNews U.S. Food and Drug Administration
Representative image illustrating preservative-free ketamine injection as NRx Pharmaceuticals secures FDA approval, marking a key milestone in addressing US drug shortages and expanding domestic pharmaceutical manufacturing.
Pharma & Biotech

Preservative-free ketamine gets FDA approval as NRx Pharmaceuticals targets US hospital supply

NRx Pharmaceuticals secures FDA approval for preservative-free ketamine. Discover what it means for drug shortages and domestic manufacturing.

Read More
Representative image of Alzheimer's disease research and brain imaging as Acumen Pharmaceuticals discontinues its experimental drug sabirnetug (ACU193) after the Phase 2 ALTITUDE-AD trial fails to slow cognitive decline despite significant amyloid plaque reduction.
Features & Analysis

Sabirnetug trial failure forces Acumen Pharmaceuticals to reassess Alzheimer’s drug development strategy

Acumen Pharmaceuticals halts sabirnetug after its Phase 2 Alzheimer's trial fails despite amyloid reduction. Discover what the findings mean.

Read More
Representative image illustrating lupus drug research as Beeline Medicines reports promising Phase 2 afimetoran results, highlighting its potential as an oral treatment for systemic lupus erythematosus.
Pharma & Biotech

Afimetoran Phase 2 trial delivers significant lupus improvement as Beeline Medicines eyes pivotal studies

Explore Beeline Medicines' Phase 2 afimetoran lupus results, showing a 30-point response advantage and promising potential for an oral therapy.

Read More
Representative image of babesiosis research and tick-borne infection testing as 60 Degrees Pharmaceuticals reports promising parasite clearance results in patients with relapsing babesiosis treated with tafenoquine-based combination therapy.
Pharma & Biotech

Tafenoquine combinations show promising parasite clearance in immunocompromised patients with babesiosis

60 Degrees Pharmaceuticals reports negative Babesia PCR tests in five patients receiving tafenoquine combinations, with FDA discussions planned.

Read More
Representative image of asthma and atopic dermatitis research as Aclaris Therapeutics’ investigational antibody ATI-052 demonstrates promising Phase 1b clinical results, reducing airway inflammation by 59% and improving eczema severity by 58%.
Pharma & Biotech

Could ATI-052 offer a new approach to asthma and eczema? Phase 1b findings support further testing

Aclaris Therapeutics' ATI-052 shows promising Phase 1b asthma and eczema results. Explore the clinical findings and upcoming Phase 2b plans.

Read More
Representative image of pancreatic cancer research as Tango Therapeutics’ vopimetostat and Revolution Medicines’ daraxonrasib combination achieves an 82% response rate in a Phase 1/2 trial.
Pharma & Biotech

Vopimetostat and daraxonrasib show strong tumor responses as Tango Therapeutics targets Phase 3

Tango Therapeutics reports 82% response with vopimetostat and daraxonrasib in pancreatic cancer. Explore the trial results and Phase 3 plans.

Read More
Representative image of ovarian cancer research as Genmab’s Rina-S shows a 57% reduction in the risk of death in a Phase 3 trial for platinum-resistant ovarian cancer.
Pharma & Biotech

Rina-S Phase 3 success brings new hope for platinum-resistant ovarian cancer patients

Genmab's Rina-S cuts the death hazard by 57% in a Phase 3 ovarian cancer trial. Explore the survival results, treatment potential and FDA outlook.

Read More
Representative image of invasive aspergillosis research as F2G and Shionogi report positive Phase 3 olorofim results, highlighting its potential as a new oral antifungal treatment.
Pharma & Biotech

Olorofim Phase 3 results show fewer kidney complications in patients with invasive aspergillosis

F2G and Shionogi's oral olorofim meets Phase 3 aspergillosis endpoint with fewer kidney adverse events. Explore the results and FDA plans.

Read More
Representative image of uveitis research as Roivant Sciences and Priovant Therapeutics report positive Phase 3 brepocitinib results, reducing treatment failure and improving steroid-free disease control.
Pharma & Biotech

Roivant and Priovant report 62% steroid-free disease control with brepocitinib in uveitis trials

Roivant's brepocitinib succeeds in two Phase 3 uveitis trials, improving steroid-free disease control. Explore the results and FDA plans.

Read More
Representative image of ulcerative colitis research as Odyssey Therapeutics’ oral drug OD-001 achieves 27% clinical remission in a Phase 2a trial, showing promising treatment potential.
Pharma & Biotech

OD-001 ulcerative colitis study shows clinical response in 61% of higher-dose patients

Odyssey Therapeutics reports 27% remission with OD-001 in Phase 2a ulcerative colitis testing. Explore the findings and next clinical trials.

Read More